Hormone pill with surgery and targeted radiation for limited prostate cancer spread
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing whether adding a new hormone pill called rezvilutamide to the usual treatment (hormone therapy plus surgery and targeted radiation) can better control prostate cancer that has spread to a few small spots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You are diagnosed with prostate cancer that has spread to a limited number of spots (no more than 10) but not to major organs like the liver, lungs, or brain.
- You are either already on or about to start hormone therapy for your prostate cancer.
- You have not previously had surgery to remove the prostate, radiation to the pelvic area, chemotherapy, or other systemic cancer treatments.
- You must be generally healthy, with adequate blood counts and organ function (evaluated by your doctor).
- If you have a partner who could become pregnant, you must agree to use effective contraception during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
This study tests adding a targeted local treatment (like radiation or surgery) to standard hormone therapy for men with advanced prostate cancer that still shows up on a special scan. The goal is to see if this combination helps control the cancer better.
This trial tests whether radiation therapy can help treat prostate cancer that has spread to only a few places in the body (oligometastatic). It aims to see if targeting both the prostate and the small number of metastases can improve outcomes.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This trial tests a new pill, Rezvilutamide, for men with prostate cancer that was removed by surgery but has features that make it more likely to come back. It's an alternative for those who don't want or can't have radiation therapy after surgery.
Hear when a new Oligometastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.